argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting
Argenx SE announced the approval of its remuneration policy at an Extraordinary General Meeting on November 18, 2025, with 95.67% majority support. The policy's approval highlights strong shareholder backing and may impact governance and stakeholder relations. The latest analyst rating for ARGX stock is a Buy with a $1124.00 price target. TipRanks’ AI Analyst rates ARGX as Outperform due to strong financial performance and bullish technical indicators, despite high valuation and cash flow challenges.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Argenx Se ( (ARGX) ).
On November 18, 2025, argenx SE announced the approval of its remuneration policy during the Extraordinary General Meeting of shareholders. The policy was approved by a 95.67% majority, with 91.1% of share capital represented, highlighting strong shareholder support and potentially impacting the company’s governance and stakeholder relations.
The most recent analyst rating on (ARGX) stock is a Buy with a $1124.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
argenx is a global immunology company focused on developing and commercializing novel antibody-based medicines for severe autoimmune diseases. Through its Immunology Innovation Program, argenx collaborates with academic researchers to advance its portfolio, including the first approved neonatal Fc receptor (FcRn) blocker.
Average Trading Volume: 364,155
Technical Sentiment Signal: Buy
Current Market Cap: $55.65B
